About Evolus
Evolus is a company based in Irvine (United States) founded in 2012. Evolus has raised $500 thousand across 3 funding rounds from investors including Daewoong Pharmaceutical. The company has 332 employees as of December 31, 2024. Evolus offers products and services including Jeuveau and Evolysse. Evolus operates in a competitive market with competitors including Revance Therapeutics, Castle Creek Pharma, Dermavant, Sol-Gel Technologies and Bausch Health, among others.
- Headquarter Irvine, United States
- Employees 332 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Evolus, Inc. Common Stock
-
Annual Revenue
$266.27 M (USD)31.76as on Dec 31, 2024
-
Net Profit
-$50.42 M (USD)18.26as on Dec 31, 2024
-
EBITDA
-$21.21 M (USD)29.84as on Dec 31, 2024
-
Total Equity Funding
$500 K (USD)
in 3 rounds
-
Latest Funding Round
$20.01 M (USD), Post-IPO
Apr 25, 2022
- Investors
-
Employee Count
332
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Evolus
Evolus is a publicly listed company on the NASDAQ with ticker symbol EOLS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Evolus
Evolus offers a comprehensive portfolio of products and services, including Jeuveau and Evolysse.
Improves appearance of moderate to severe frown lines temporarily.
Softens dynamic facial wrinkles and folds via injection.
People of Evolus
Unlock access to complete
Unlock access to complete
Funding Insights of Evolus
Evolus has successfully raised a total of $500K across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $20.01 million completed in April 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Evolus
Evolus has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Daewoong Pharmaceutical.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Therapies for gastrointestinal disorders and related diseases are developed.
|
Locked | Locked | Locked |
Investor details for Evolus
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Evolus
Investment portfolio details for Evolus
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Evolus
Detailed financials for Evolus
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Evolus Comparisons
Peer comparison for Evolus
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Evolus
Evolus operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Revance Therapeutics, Castle Creek Pharma, Dermavant, Sol-Gel Technologies and Bausch Health, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Neurotoxin products for aesthetic and therapeutic skin treatments are developed.
|
|
| Locked | Locked | Locked |
Drugs for skin diseases, ENT disorders, and rare diseases such as urea cycle disorders
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for inflammatory skin diseases are developed.
|
|
| Locked | Locked | Locked |
Developing topical drug products for the treatment of rosacea, acne and interdigital tinea pedis.
|
|
| Locked | Locked | Locked |
Therapeutics for multiple diseases including dermatology and neurology are developed.
|
|
| Locked | Locked | Locked |
Therapeutics in aesthetics are developed, including botulinum toxin products.
|
Detailed competitors of Evolus
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Evolus
Complete news archive for Evolus
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Evolus
Evolus was founded in 2012 and raised its 1st funding round 1 year after it was founded.
Evolus is headquartered in Irvine, United States. It is registered at Irvine, California, United States.
Murthy Simhambhatla is the current CEO of Evolus.
Evolus is a funded company, having raised a total of $500K across 3 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Evolus is 332.
Annual revenue of Evolus is $266.27M as on Dec 31, 2024.
Evolus was founded in 2012 and is headquartered in Irvine, United States. Operations center on the development of self-pay aesthetic products within the biotechnology sector. The lead product candidate, DWP-450, an injectable 900 kDa purified botulinum toxin type A complex, is currently in Phase II clinical trials for moderate-to-severe glabellar lines. Focus remains on advancing injectable aesthetic solutions.
Evolus's top competitors include Revance Therapeutics, Dermavant and Bausch Health.
Evolus offers Jeuveau and Evolysse.
Yes, Evolus is publicly traded on NASDAQ under the ticker symbol EOLS.
Evolus has 1 investor. Key investors include Daewoong Pharmaceutical.
The ticker symbol of Evolus is EOLS on NASDAQ.